Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$124.25 USD
+7.13 (6.09%)
Updated Apr 24, 2024 04:00 PM ET
2-Buy of 5 2
D Value B Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SRPT 124.25 +7.13(6.09%)
Will SRPT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SRPT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SRPT
Vanda (VNDA) to Report Q1 Earnings: What's in the Cards?
Insulet (PODD) Awaits Q1 Earnings Release: Here's What to Expect
SRPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
GSK Gears Up for Q1 Earnings: Here's What to Expect
Incyte (INCY) to Report Q1 Earnings: What's in the Cards?
AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?
Other News for SRPT
Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
Edgewise gets EU orphan drug status for muscular dystrophy drug
Analysts Offer Insights on Healthcare Companies: Elevance Health (ELV), Sarepta Therapeutics (SRPT) and Intuitive Surgical (ISRG)
As more rare disease therapies launch, their prices are rising
Noteworthy Thursday Option Activity: SRPT, GFF, ADBE